United Therapeutics

Update in progress

UTHR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

United Therapeutics Corporation develops and markets therapies for chronic and life-threatening diseases in the United States and globally. Its products include Tyvaso DPI and Nebulized Tyvaso (treprostinil), Remodulin injections, Orenitram (treprostinil tablet), and Adcirca (tadalafil) for pulmonary arterial hypertension. It markets Unituxin for high-risk neuroblastoma and Remunity Pump, and pursues programs such as Ralinepag, RemunityPRO, xenotransplantation, and regenerative medicine. Collaborations include DEKA, MannKind, and Arena. Founded 1996, Silver Spring, MD.

Company score

Sentiment: 0.52; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.44; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.18; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.17; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive